641569-97-3

Basic information

• Product Name: 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoic acid ethyl ester
• Synonyms: 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoic acid ethyl ester;Benzoic acid, 4-Methyl-3-[[4-(3-pyridinyl)-2-pyriMidinyl]aMino]-, ethyl ester;Ethyl 4-Methyl-3-((4-(pyridin-3-yl)pyriMidin-2-yl)aMino)benzoate;Ethyl 4-methyl-3-((4-(pyridin-3-yl)
• CAS NO: 641569-97-3
• Molecular Formula: C19H18N4O2
• Molecular Weight: 334.37
• Mol File: 641569-97-3.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 546.1 °C at 760 mmHg
• Flash Point: 284.1 °C
• Appearance: /
• Density: 1.233
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• CAS DataBase Reference: 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoic acid ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoic acid ethyl ester(641569-97-3)
• EPA Substance Registry System: 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoic acid ethyl ester(641569-97-3)

Safety Data

• Hazardous Substances Data: 641569-97-3(Hazardous Substances Data)

Usage

Description

4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoic acid ethyl ester, also known as Ethyl 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoate, is a chemical compound with a complex structure that features a benzoic acid core, an ethyl ester group, and a pyrimidinyl-pyridinyl amino side chain. This molecule is characterized by its potential applications in the pharmaceutical industry, particularly in the synthesis of various drugs.

Uses

Used in Pharmaceutical Synthesis:
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoic acid ethyl ester is used as an intermediate in the synthesis of Nilotinib-d6 (N465303), which is a labeled analogue of Nilotinib. Nilotinib is a tyrosine kinase inhibitor that is primarily used in the treatment of chronic myelogenous leukemia (CML). 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoic acid ethyl ester plays a crucial role in the development of this therapeutic agent, contributing to its efficacy and potential for targeted cancer treatment.
Used in Smo Inhibitor Preparation:
In the pharmaceutical industry, 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoic acid ethyl ester is also utilized in the preparation of Smoothened (Smo) inhibitors. Smo inhibitors are a class of drugs that target the Smo protein, which is involved in the Hedgehog signaling pathway. This pathway plays a critical role in cell differentiation and tissue development, and its dysregulation has been linked to various cancers. By inhibiting Smo, these compounds can potentially slow down or halt tumor growth, making them valuable in the development of anticancer drugs.
Used in Synthesis and Application of Related Compounds:
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoic acid ethyl ester is employed in the synthesis of other related compounds that may have various applications in the pharmaceutical and chemical industries. Its unique structure and functional groups make it a versatile building block for the development of new molecules with potential therapeutic or industrial uses. 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoic acid ethyl ester's role in these syntheses highlights its importance in the broader context of chemical research and drug discovery.

Upstream product

• 2458-12-0 3-amino-p-toluic acid 
• 41191-92-8 3-amino-4-methylbenzoic acid ethyl ester 
• 641569-95-1 C₁₁H₁₅N₃O₂ 
• 55314-16-4 3-(N,N-dimethylamino)-1-(pyridin-3-yl)prop-2-en-1-one 
• 483324-01-2 2-chloro-4-(pyridin-3-yl)pyrimidine 
• 350-03-8 methyl-3-pyridylketone 
• 7697-26-9 3-bromo-4-methylbenzoic acid 
• 147962-81-0 ethyl 3-bromo-4-methylbenzoate 
• 66521-66-2 4-pyridin-3-ylpyrimidin-2-ylamine 
• 19013-15-1 ethyl 4-methyl-3-nitro-benzoate 
• 96-98-0 4-methyl-3-nitrobenzoic acid 
• 641569-96-2 3-guanidino-4-methylbenzoic acid ethyl ester nitrate 

Downstream Products

• 851138-04-0 4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)-N-(3-(trifluoromethyl)phenyl)benzamide 
• 1205540-17-5 4-methyl-3-[[4-(3-pyridyl)-2-pyrimidinyl]amino]benzoyl chloride 
• 641570-12-9 C₂₀H₁₆N₆OS 
• 1205540-16-4 N-(3-bromo-5-(trifluoromethyl)phenyl)-4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)benzamide 

Relevant articles and documents

Method for preparing N-(5-carboxyl-2-methylphenyl)-4-(3-pyridine)-2-pyrilamine

The invention discloses a method for preparing N-(5-carboxyl-2-methylphenyl)-4-(3-pyridine)-2-pyrilamine. The method specifically comprises the following steps: step 1, carrying out ethyl esterification reaction on 3-nitro-4-methyl benzoic acid serving as an initial raw material to generate a compound 2; step 2, reducing nitro of the compound 2 through hydrogenation reduction reaction in the presence of palladium on carbon to generate a compound 3; step 3, reacting the compound 3 with a nitrile amine aqueous solution, and then carrying out base exchange to obtain a compound 4; step 4, carrying out cyclization between the compound 4 and a compound 6 to obtain a compound 7; and step 5, hydrolyzing the compound 7 under the action of an alkaline to generate a compound 8, namely N-(5-carboxyl-2-methylphenyl)-4-(3-pyridine)-2-pyrilamine. The method overcomes the defects that in the prior art such as long reaction time, low yield, high cost, difficulty for industrial production, and the like. A preparation method, which is high in yield, is environmentally-friendly, and is suitable for industrial production, is provided.

Smo inhibitor as well as synthesis method and application thereof

The invention discloses an Smo inhibitor as well as a synthesis method and application thereof. A structural formula of the Smo inhibitor is shown by a formula (I) as shown in the specification. The invention also discloses the synthesis method and the application of the Smo inhibitor. According to the invention, nilotinib is optimized into the dual-targeted inhibitor being active against Smo andBcr-Abl, and the inhibitor can overcome the tolerance problem caused by single-targeted drugs, has the advantages of improving anti-tumor efficacy and reducing toxic or side effects, and provides a reference for future research on dual-targeted anti-hematologic malignant drugs.

Preparing method for 4-methyl-3-[[4-(3-pyridyl)-2-pyrimidyl]amidogen]ethyl benzoate

The invention relates to a preparing method for 4-methyl-3-[[4-(3-pyridyl)-2-pyrimidyl]amidogen]ethyl benzoate and belongs to the technical field of compound synthesis. The preparing method comprises the following steps of using triacetyl pyridine as a beginning raw material, condensing a product generated after urea loop closing and carbonyl chloro substitution with 3-amino-4-methyl ethyl benzoate to generate a key intermediate (I). Compared with an existing synthetic method, the preparing method is moderate in reacting condition and high in yield and has practical value. In addition, the raw material of the preparing method is cheap, easy to obtain and low in price. A synthetic route of the preparing method is as follow in the specification.